
Black Americans are far less likely to be included in clinical trials of pancreatic cancer drugs than white Americans, and eligibility criteria are a significant factor in that gap, according to a new study. “The standard of care in cancer treatment is informed by studies conducted with predominantly non-Hispanic white patients,” said study author Dr.… read on > read on >